探索GABAA受体调节的DS2支架:朝着开发一个GABAA δ-子单元偏好负基调节器的进展
Nicoline N Jensen1, Kristine S Wilhelmsen1, Malene Hall Jensen1
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.
Journal of medicinal chemistry
|February 2, 2026
概括
研究人员开发了一种新型化合物,1e,可以选择性地向含有delta的GABA-A受体. 该化合物作为负基调节剂,具有治疗特征为过度增强抑制的神经系统疾病的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 含有甲型γ-氨基黄油酸受体 (GABAARs) 的突突触三角质受体与神经系统疾病有关,原因是性抑制发生变化.
- 化合物DS2是已知的 δ-GABAARs 的选择性调节器,作为一种有价值的研究工具.
研究的目的:
- 合成和表征具有修改药理特征的新型DS2类似物.
- 为了识别具有选择性负度调节 δ-GABAARs.的化合物.
主要方法:
- 合成DS2类似物,包括含有N-甲基化pyrrolyl环的化合物1e.
- 对复合GABAAR亚型的化合物1e的电生理学评估.
- 评估化合物1e对具有与神经系统疾病相关的功能获取突变的受体的活性.
主要成果:
- 化合物1e表现出 δ-GABAARs 的负基调制,与DS2 的积极调制形成鲜明对比.
- 1e对δ-GABAAR亚型具有选择性,而对含有γ2亚型没有活性.
- 它有效地减少了与神经发育障碍和相关的突变受体中的GABA电流.
结论:
- 化合物1e是 δ-GABAARs.的选择性负基调节器.
- 1e的脑透性和减少过度增强抑制的能力使其成为神经疾病的有希望的化合物.
相关概念视频
Cooperative Allosteric Transitions
8.7K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.7K
Cooperative Allosteric Transitions
2.7K
2.7K
Cooperative Allosteric Transitions
3.1K
3.1K
Internal Receptors
74.7K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K
G-protein Coupled Receptors
132.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
908
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
908


